{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:58:04Z","timestamp":1789138684624,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Cancer Institute","award":["F99CA264445-01"],"award-info":[{"award-number":["F99CA264445-01"]}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM121322"],"award-info":[{"award-number":["P20GM121322"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mylan Chair Endowment Fund"},{"DOI":"10.13039\/100012639","name":"METAvivor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012639","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lung cancer is the most common primary tumor to metastasize to the brain. Although advances in lung cancer therapy have increased rates of survival over the past few decades, control and treatment of lung cancer brain metastasis remains an urgent clinical need. Herein, we examine the temporal coordination of \u03b1-CTLA-4 administration in combination with whole-brain radiation therapy in a syngeneic preclinical model of lung cancer brain metastasis in both C57Bl\/6 and athymic nude mice. Brain tumor burden, survival, and weight loss were monitored. Immunotherapy administration 24\u00a0h prior to irradiation resulted in increased brain tumor burden, while administration of immunotherapy 12\u00a0h after radiation decreased tumor burden. Neither of the treatments affected survival outcomes or weight loss due to brain tumor recurrence. These findings suggest that the coordination of \u03b1-CTLA-4 administration in addition to whole-brain radiation therapy may be a viable strategy for reduction of tumor burden for the management of lung cancer brain metastasis.<\/jats:p>","DOI":"10.1007\/s00262-023-03599-w","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T11:01:48Z","timestamp":1705662108000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Coordination of anti-CTLA-4 with whole-brain radiation therapy decreases tumor burden during treatment in a novel syngeneic model of lung cancer brain metastasis"],"prefix":"10.1007","volume":"73","author":[{"given":"K. E.","family":"Blethen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. P.","family":"Wolford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. L.","family":"Pecar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. A.","family":"Arsiwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Adjeroh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. P.","family":"Dykstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. N.","family":"Kielkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. R.","family":"Lockman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"issue":"5","key":"3599_CR1","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/0284186X.2021.2013529","volume":"61","author":"L Lofling","year":"2022","unstructured":"Lofling L et al (2022) Temporal trends in lung cancer survival: a population-based study. Acta Oncol 61(5):625\u2013631","journal-title":"Acta Oncol"},{"issue":"1","key":"3599_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12890-022-01936-w","volume":"22","author":"J Yuan","year":"2022","unstructured":"Yuan J et al (2022) Prognosis of lung cancer with simple brain metastasis patients and establishment of survival prediction models: a study based on real events. BMC Pulm Med 22(1):162","journal-title":"BMC Pulm Med"},{"issue":"6","key":"3599_CR3","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1200\/JCO.22.01503","volume":"41","author":"JR Brahmer","year":"2023","unstructured":"Brahmer JR et al (2023) Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in checkmate 227. J Clin Oncol 41(6):1200\u20131212","journal-title":"J Clin Oncol"},{"issue":"10212","key":"3599_CR4","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394(10212):1929\u20131939","journal-title":"Lancet"},{"issue":"21","key":"3599_CR5","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck M et al (2021) Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score >\/= 50. J Clin Oncol 39(21):2339\u20132349","journal-title":"J Clin Oncol"},{"issue":"5","key":"3599_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2217\/fon-2020-0701","volume":"17","author":"A Veccia","year":"2021","unstructured":"Veccia A et al (2021) Management of brain metastases from lung cancer in the era of immunotherapy: a review of the literature. Future Oncol 17(5):597\u2013609","journal-title":"Future Oncol"},{"key":"3599_CR7","doi-asserted-by":"publisher","first-page":"852811","DOI":"10.3389\/fimmu.2022.852811","volume":"13","author":"G Yang","year":"2022","unstructured":"Yang G, Xing L, Sun X (2022) Navigate towards the immunotherapy era: value of immune checkpoint inhibitors in non-small cell lung cancer patients with brain metastases. Front Immunol 13:852811","journal-title":"Front Immunol"},{"issue":"1","key":"3599_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cllc.2020.10.017","volume":"22","author":"L Sun","year":"2021","unstructured":"Sun L et al (2021) Outcomes in patients with non-small-cell lung cancer with brain metastases treated with pembrolizumab-based therapy. Clin Lung Cancer 22(1):58\u201366","journal-title":"Clin Lung Cancer"},{"key":"3599_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006127","author":"NE Ready","year":"2023","unstructured":"Ready NE et al (2023) First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-006127","journal-title":"J Immunother Cancer"},{"issue":"8","key":"3599_CR10","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.jtho.2023.04.021","volume":"18","author":"M Reck","year":"2023","unstructured":"Reck M et al (2023) Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic NSCLC and baseline brain metastases from checkmate 227 Part 1. J Thorac Oncol 18(8):1055\u20131069","journal-title":"J Thorac Oncol"},{"issue":"5","key":"3599_CR11","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","volume":"9","author":"W Theelen","year":"2021","unstructured":"Theelen W et al (2021) Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med 9(5):467\u2013475","journal-title":"Lancet Respir Med"},{"key":"3599_CR12","doi-asserted-by":"publisher","first-page":"952066","DOI":"10.3389\/fimmu.2022.952066","volume":"13","author":"Y Kong","year":"2022","unstructured":"Kong Y et al (2022) PD-1 Inhibitor combined with radiotherapy and GM-CSF (PRaG) in Patients with metastatic solid tumors: an open-label phase II study. Front Immunol 13:952066","journal-title":"Front Immunol"},{"key":"3599_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006871","author":"M Altan","year":"2023","unstructured":"Altan M et al (2023) Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I\/II trial. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2023-006871","journal-title":"J Immunother Cancer"},{"issue":"20","key":"3599_CR14","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1158\/0008-5472.CAN-20-0291","volume":"80","author":"M Valiente","year":"2020","unstructured":"Valiente M et al (2020) Brain metastasis cell lines panel: a public resource of organotropic cell lines. Cancer Res 80(20):4314\u20134323","journal-title":"Cancer Res"},{"issue":"1","key":"3599_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13014-023-02215-6","volume":"18","author":"KE Blethen","year":"2023","unstructured":"Blethen KE et al (2023) Effects of whole-brain radiation therapy on the blood-brain barrier in immunocompetent and immunocompromised mouse models. Radiat Oncol 18(1):22","journal-title":"Radiat Oncol"},{"issue":"12","key":"3599_CR16","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","volume":"24","author":"SC Formenti","year":"2018","unstructured":"Formenti SC et al (2018) Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med 24(12):1845\u20131851","journal-title":"Nat Med"},{"issue":"7547","key":"3599_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor C et al (2015) Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520(7547):373\u2013377","journal-title":"Nature"},{"issue":"3","key":"3599_CR18","doi-asserted-by":"publisher","first-page":"e92572","DOI":"10.1371\/journal.pone.0092572","volume":"9","author":"Y Yoshimoto","year":"2014","unstructured":"Yoshimoto Y et al (2014) Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model. PLoS ONE 9(3):e92572","journal-title":"PLoS ONE"},{"issue":"8","key":"3599_CR19","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1359\/jbmr.2001.16.8.1486","volume":"16","author":"T Yoneda","year":"2001","unstructured":"Yoneda T et al (2001) A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 16(8):1486\u20131495","journal-title":"J Bone Miner Res"},{"issue":"1","key":"3599_CR20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12885-020-06808-2","volume":"20","author":"N Shah","year":"2020","unstructured":"Shah N et al (2020) Drug resistance occurred in a newly characterized preclinical model of lung cancer brain metastasis. BMC Cancer 20(1):292","journal-title":"BMC Cancer"},{"issue":"169","key":"3599_CR21","first-page":"e61692","volume":"11","author":"SA Sprowls","year":"2021","unstructured":"Sprowls SA, Pizzuti VJ, Pentz W, Nwafor DC, Siochi RA, Lockman PR (2021) Irradiator commissioning and dosimetry for assessment of LQ \u03b1 and \u03b2 parameters, radiation dosing schema, and in vivo dose deposition. JoVE (J Vis Exp) 11(169):e61692","journal-title":"JoVE (J Vis Exp)"},{"key":"3599_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1159\/000331200","volume":"25","author":"AL Stockham","year":"2012","unstructured":"Stockham AL et al (2012) Management of recurrent brain metastasis after radiosurgery. Prog Neurol Surg 25:273\u2013286","journal-title":"Prog Neurol Surg"},{"issue":"17","key":"3599_CR23","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627\u20131639","journal-title":"N Engl J Med"},{"issue":"35","key":"3599_CR24","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","volume":"35","author":"L Horn","year":"2017","unstructured":"Horn L et al (2017) Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (checkmate 017 and checkmate 057). J Clin Oncol 35(35):3924\u20133933","journal-title":"J Clin Oncol"},{"issue":"1","key":"3599_CR25","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/jcmm.13956","volume":"23","author":"H Zhang","year":"2019","unstructured":"Zhang H et al (2019) Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer. J Cell Mol Med 23(1):535\u2013542","journal-title":"J Cell Mol Med"},{"issue":"6","key":"3599_CR26","first-page":"358","volume":"42","author":"JC Kim","year":"2005","unstructured":"Kim JC et al (2005) Correlation of HER1\/EGFR expression and degree of radiosensitizing effect of the HER1\/EGFR-tyrosine kinase inhibitor erlotinib. Indian J Biochem Biophys 42(6):358\u2013365","journal-title":"Indian J Biochem Biophys"},{"issue":"3","key":"3599_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00066-005-1319-5","volume":"181","author":"S Burdak-Rothkamm","year":"2005","unstructured":"Burdak-Rothkamm S et al (2005) Radiosensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa). Strahlenther Onkol 181(3):197\u2013204","journal-title":"Strahlenther Onkol"},{"issue":"5","key":"3599_CR28","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.ijrobp.2021.11.023","volume":"112","author":"G Chen","year":"2022","unstructured":"Chen G et al (2022) Golgi phosphoprotein 3 confers radioresistance via stabilizing EGFR in lung adenocarcinoma. Int J Radiat Oncol Biol Phys 112(5):1216\u20131228","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1A","key":"3599_CR29","first-page":"1","volume":"22","author":"VW Lui","year":"2002","unstructured":"Lui VW, Grandis JR (2002) EGFR-mediated cell cycle regulation. Anticancer Res 22(1A):1\u201311","journal-title":"Anticancer Res"},{"issue":"4","key":"3599_CR30","doi-asserted-by":"publisher","first-page":"155932581989100","DOI":"10.1177\/1559325819891008","volume":"17","author":"C Liu","year":"2019","unstructured":"Liu C et al (2019) The cell cycle G2\/M block is an indicator of cellular radiosensitivity. Dose Response 17(4):1559325819891008","journal-title":"Dose Response"},{"issue":"3","key":"3599_CR31","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1124\/jpet.119.257717","volume":"370","author":"SY Jung","year":"2019","unstructured":"Jung SY et al (2019) Radiosensitizing effect of novel phenylpyrimidine derivatives on human lung cancer cells via cell cycle perturbation. J Pharmacol Exp Ther 370(3):514\u2013527","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"3599_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13014-020-01493-8","volume":"15","author":"Y Tien","year":"2020","unstructured":"Tien Y et al (2020) Targeting human epidermal growth factor receptor 2 enhances radiosensitivity and reduces the metastatic potential of Lewis lung carcinoma cells. Radiat Oncol 15(1):58","journal-title":"Radiat Oncol"},{"key":"3599_CR33","doi-asserted-by":"publisher","first-page":"608024","DOI":"10.3389\/fimmu.2020.608024","volume":"11","author":"D Oyewole-Said","year":"2020","unstructured":"Oyewole-Said D et al (2020) Beyond T-cells: functional characterization of CTLA-4 expression in immune and non-immune cell types. Front Immunol 11:608024","journal-title":"Front Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03599-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03599-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03599-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T13:09:07Z","timestamp":1707570547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03599-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["3599"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03599-w","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"3 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal experiments were approved by the Institutional Animal Care and Use Committee at West Virginia University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"20"}}